Company intelligence / Profile preview

Praetego

Durham, North Carolina, United Statespraetego.com ↗
Ownership
Private
Development stage
Preclinical
01

Overview

Praetego’s lead candidate PTG‑630 has demonstrated neuroprotection in preclinical models of AD and DPN, showing protection against mild cognitive impairment and biomarker evidence of neuronal benefit. IND-enabling studies are ongoing with an IND filing planned for late 2024. The company has received multiple NIH grants to advance its programs toward clinical trials.

A Phase 2 study will target diabetics with mild cognitive impairment at high risk for AD to demonstrate target engagement and proof of mechanism.

Additional preclinical work supports expansion into diabetic retinopathy as a third indication.

No human clinical results reported yet.
Therapeutic areas
OphthalmologyEndocrinologyNeurology
Modalities
Small molecules (Amadorins)
Industry
Biotech
02

Drug pipeline

1 asset

PTG-630

Unknown
03

Partnerships

Collaboration with Penn State University on diabetic retinopathy researchCollaboration with University of California at San Diego School of Medicine on CNS diseases

Beyond the preview

Go deeper on Praetego.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Praetego.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call